Aimmune Therapeutics (Aimmune Therapeutics) Debt-to-Equity : 0.80 (As of Jun. 2020)

View and export this data going back to 2015. Start your Free Trial

What is Aimmune Therapeutics Debt-to-Equity?

Aimmune Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2020 was $2.40 Mil. Aimmune Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2020 was $140.79 Mil. Aimmune Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2020 was $179.86 Mil. Aimmune Therapeutics's debt to equity for the quarter that ended in Jun. 2020 was 0.80.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Aimmune Therapeutics's Debt-to-Equity or its related term are showing as below:

AIMT' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.2 Med: 0.43 Max: 0.8
Current: 0.8

During the past 7 years, the highest Debt-to-Equity Ratio of Aimmune Therapeutics was 0.80. The lowest was 0.20. And the median was 0.43.

AIMT's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs AIMT: 0.80

Aimmune Therapeutics Debt-to-Equity Historical Data

The historical data trend for Aimmune Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aimmune Therapeutics Debt-to-Equity Chart

Aimmune Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Debt-to-Equity

Get a 7-Day Free Trial

0.52

Aimmune Therapeutics Quarterly Data
	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20
Debt-to-Equity	Get a 7-Day Free Trial															0.25	0.35	0.52	0.60	0.80

Competitive Comparison of Aimmune Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Aimmune Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aimmune Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aimmune Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Aimmune Therapeutics's Debt-to-Equity falls into.

Aimmune Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Aimmune Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2019 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.257	+	51.552)	/	104.024
	=	0.52

Aimmune Therapeutics's Debt to Equity Ratio for the quarter that ended in Jun. 2020 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.399	+	140.785)	/	179.858
	=	0.80

Aimmune Therapeutics (NAS:AIMT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Aimmune Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Aimmune Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Aimmune Therapeutics (Aimmune Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aimmune Therapeutics Inc (NAS:AIMT) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

8000 Marina Boulevard, Suite 300, Brisbane, CA, USA, 94005

Website

https://www.aimmune.com

Aimmune Therapeutics Inc is a company operating in the United States biotechnology industry. Its main focus is in the development of product candidates to combat peanut and other food allergies. The company's therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy, is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols, and support services.

Executives

Gregory Behar	director	C/O SERES HEALTH, INC., 161 FIRST STREET, CAMBRIDGE MA 02472
Societe Des Produits Nestle S.a.	10 percent owner	AVENUE NESTLE 55, VEVEY V8 CH-1800
Kathryn E Falberg	director	C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Andrew Oxtoby	officer: Chief Commercial Officer	8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005
Dallas Jayson Donald Alexander	director, officer: President and CEO	AIMMUNE THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005
Stacey Denenberg Seltzer	director	C/O AISLING CAPITAL, 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Brett K Haumann	director	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Douglas T. Sheehy	officer: See Remarks	C/O AIMMUNE THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005-1884
Mark T Iwicki	director	84 WATERFORD DRIVE, MARLBOROUGH MA 01752
Patrick G Enright	director	CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Mark Mcdade	director	C/O PROTINE DESIGN LAB, 7442 NORTH MARCER WAY, MERCER ISLAND WA 98040
Adelman Daniel C Md	officer: Chief Medical Officer	23 WOODLEAF AVENUE, REDWOOD CITY CA 94061
Eric Bjerkholt	officer: Chief Financial Officer	132 PURDURE AVENUE, KENGSINGTON CA 94708
Sa Nestle	10 percent owner	AVE NESTLE 55, CH-1800, VEVEY V8
Mary M. Rozenman	officer: See Remarks	AIMMUNE THERAPEUTICS, INC. 8000 MARINA BOULEVARD, SUITE 300 BRISBANE CA 94005